Location

Gene

Polymorphism(s)

Risk genotype

Number of studies (cases)

Size of effect
(95% CI)

Reference

1p36.3

MTHFR Methylenetetrahydrofolate reductase

C677T

TT

40(11,162)

1.14 (1.01-1.28)

[70]

1q23

F5 Factor V Leiden

R506Q

Q+

20(5,313)

1.10(0.88-1.36)

[69]

1q42.2

AGTAngiotensinogen

Met235Thr(M235T)

TT

21(4,001)

1.19 (1.10-1.30)

[64]

2p24-p23

APOB Apolipoprotein B

Gln4154Lys (Q4154L)

LL

14(1,796)

1,73(1.19-2.50)

[75]

2p24-p23

APOB Apolipoprotein B

Signal peptide Ins/Del

DD

22(6,007)

1.19 (1.05-1.35)

[75]

7q21.3

PON1 Paraoxonase

Q192R

R192

44 (10,106)

1.12 (1.07-1.16)

[65]

7q21.3-q22

PAI-1 Plasminogen activator inhibitor type 1

5G/4G

4G4G

7(2,813)

1.20 (1.04-1.39)

[73]

7q36

NOS3 Nitric oxide synthase 3

Glu298Asp (E298D)

DD

14(6,036)

1.31(1.13-1.51)

[74]

8p22

LPL Lipoprotein lipase

Ser/Ter(S447X)

X+

4(2,252)

0.80(0.7-1.0)

[66]

11p11

F2 Prothrombin

G20210A

A+

19(4,944)

1.21(0.99-1.58)

[71]

16q21

CETPCholesteryl estertransfer protein

TaqIB

B2B2

7(7,681)

0.78(0.66-0.93)

[72]

17q21.32

ITGB3Platelet glycoprotein IIIa

PL(A1/A2)

A2+

34(6,173)

1.13(1.02-1.26)

[67]

17q23.3

ACE Angiotensin I converting enzyme

Insertion/Deletion

DD

43(14,292)

1.22(1.11-1.35)

[67]

19q13.2

APOE Apolipoprotein E

E2, E3, E4

e4

48(15,492)

1.30(1.18-1.51)

[68]

Table 1: List of gene variants with published meta-analysis on CAD risk and more than 2000 cases [76].